The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists.
Exenatide (PubChem CID: 45588096)
Glucagon-like peptide 1
Immune system
Inflammation
Liraglutide (PubChem CID: 16134956)
Lymphocytes
Macrophages
Semaglutide (PubChem CID: 56843331)
Journal
Pharmacological research
ISSN: 1096-1186
Titre abrégé: Pharmacol Res
Pays: Netherlands
ID NLM: 8907422
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
received:
30
05
2022
revised:
16
06
2022
accepted:
16
06
2022
pubmed:
24
6
2022
medline:
10
8
2022
entrez:
23
6
2022
Statut:
ppublish
Résumé
In the last few years, a great interest has emerged in investigating the pleiotropic effects of Glucagon Like Peptide-1 Receptor Agonists (GLP-1RAs). While GLP-1RAs ability to lower plasma glucose and to induce weight loss has allowed them to be approved for the treatment of diabetes and obesity, consistent evidences from in vitro studies and preclinical models suggested that GLP-1RAs have anti-inflammatory properties and that may modulate the immune-system. Notably, such anti-inflammatory effects target different pathways in different tissues, underling the broad spectrum of GLP-1RAs actions. This review examines some of the currently proposed molecular mechanisms of GLP-1RAs actions and explores their potential benefits in reducing inflammatory responses, which may well suggest a future therapeutic use of GLP-1RAs in new indications.
Identifiants
pubmed: 35738455
pii: S1043-6618(22)00265-1
doi: 10.1016/j.phrs.2022.106320
pii:
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Glucagon-Like Peptide-1 Receptor
0
Hypoglycemic Agents
0
Liraglutide
839I73S42A
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
106320Informations de copyright
Copyright © 2022 Elsevier Ltd. All rights reserved.